Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Velocity Clinical Research appoints Justin Starzyk as Chief Executive OfficerVelocity Clinical Research names growth-focused healthcare operator Justin Starzyk as CEO to lead its next growth chapter
- Theralase Technologies Inc.Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial StatementsTheralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)Toronto, Ontario--(September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and...
- Radisson to Participate in The Gentile Mining Investor Forum in LondonRouyn-Noranda, Quebec, Sept 18, 2026 - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") today announced its participation in the inaugural Gentile Mining Investor Forum (the "Forum"), a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. ("Amvest Capital") and made possible by the generous support of Flagship Sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. "I created this program to give serious investors direct, in-person access to a select group of companies I've backed with conviction. Each one represents what I believe to be a high-potential opportunity in the mining sector. These are names I have researched deeply, invested in personally, and believe have the potential to deliver meaningful value. Amvest Capital has been an outstanding partner in building a week of events that meets the standards these investors and companies deserve," said Michael Gentile. The Forum will bring together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile's portfolio, including Radisson. The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor.Events. Crux Investor serves as the Forum's media sponsor. "We are pleased to participate in the inaugural Gentile Mining Investor Forum in London, an important opportunity to engage directly with a sophisticated audience of investors," commented Radisson President and CEO, Matt Manson. "The O'Brien Gold Project is at an exciting stage of development, with our fully-funded 140,000-metre step-out drill program ongoing with eight drill rigs and a recently completed C$57 million investment by Agnico Eagle Mines Limited to support an advanced underground exploration program. We look forward to sharing with investors the outlook for the O'Brien Gold Project and the investment merits for Radisson." Registration Investor registration is now open. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com. About Radisson Mining Radisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 PEA described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.63 Moz (3.49 Mt at 5.59 g/t Au), with additional Inferred Mineral Resources estimated at 1.69 Moz (10.37 Mt at 5.08 g/t Au). Please see the NI 43-101 "O'Brien Gold Project Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025, Radisson's news release dated March 2, 2026 "With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate" and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the O'Brien Gold Project. About Michael Gentile Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada's largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards. About Amvest Capital Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com. For more information on Radisson, visit our website at www.radissonmining.com or contact: Matt Manson President and CEO 416.618.5885 [email protected] Kristina Pillon Manager, Investor Relations 604.908.1695 [email protected] Forward-Looking Statements This news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the ability to execute the Company's plans relating to the O'Brien Gold Project as set out in the Preliminary Economic Assessment; the Company's ability to complete its planned exploration and development programs; the absence of adverse conditions at the O'Brien Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the O'Brien Gold Project profitable; the Company's ability to continue raising necessary capital to finance its operations; the ability to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies; local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; planned and ongoing drilling; the significance of drill results; the ability to continue drilling; the impact of drilling on the definition of any resource; and the ability to incorporate new drilling in an updated technical report and resource modelling; the Company's ability to grow the O'Brien Gold Project; and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements. Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others; the risk that the O'Brien Gold Project will never reach the production stage (including due to a lack of financing); the Company's capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company's activities; price volatility and availability of commodities; instability in the global financial system; the effects of high inflation, such as higher commodity prices; the risk of any future litigation against the Company; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; risks relating to the drill results at O'Brien; the significance of drill results; and the ability of drill results to accurately predict mineralization. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release. Please refer to the "Risks and Uncertainties Related to Exploration" and the "Risks Related to Financing and Development" sections of the Company's Management's Discussion and Analysis dated April 23, 2026 for the year ended December 31, 2025 available electronically on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
- Edopi Health Care ClinicEdopi Health Care Clinic Highlights Breast Implant Care as Vietnam Expands Focus on Medical TourismAs Vietnam continues to develop its healthcare offerings for international visitors, specialized medical and aesthetic services are becoming part of the broader conversation around the country's medical tourism potential. Against...
- Investeringsforeningen IA Invest – Udskydelse af overflytning af tre afdelingerI forlængelse af foreningens meddelelse af 23. juni 2026 om generalforsamlingens vedtagelse af overflytning af afdelingerne Strategic Danske Aktier, Advice Capital Global og Advice Capital Breakthrough Biotech til Investeringsforeningen PortfolioManager, skal det hermed oplyses, at overflytningen af de tre afdelinger er blevet udskudt, da Finanstilsynet endnu ikke har godkendt overflytningen.
- Vyne Sharpens Focus on Dental With Sale of Vyne Medical to MROStrategic sale of Vyne Medical to MRO concentrates leadership, capital, and product investment in dental RCM
- Cuprina Holdings (Cayman) Limited Announces Closing of Public OfferingCuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the closing of its previously announced public offering of an aggregate 4,322,489 Class A Ordinary Shares (“the Offering”) at a price of $1.15 per share (“the Offering Price”) to the public, for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.
- Immumax Expands Global Access to the E-Tapper to Empower Natural Health Management from HomeImmumax announces the global expansion of its online training and consultation services for the e-Tapper natural wellness device.
- Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public OfferingElectra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The gross proceeds to Electra from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Electra, are expected to be approximately $350.0 million. In addition, Electra has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Electra.
- Riyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia's Commitment to Lead the Future of BiotechnologyRIYADH, KSA, Sept 18, 2026 - The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia's ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom's leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place. More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh. The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony. Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit's work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love. FOUR PILLARS, ONE NATIONAL MISSION RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom's entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom's essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities' Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master's programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon. THREE DAYS ON THE MAIN STAGE Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony. "RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope. "Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families." H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS . RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom's place at the forefront of global biotechnology in the years ahead. About The Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org FOR FURTHER INFORMATION Email: [email protected] Telephone: +966 559 810 777
- RGMBS 2026 Life Sciences Innovation Forum Draws More Than USD 120 Million in Investor Interest as 23 Global Biotech Innovators Pitch in RiyadhRIYADH, KSA, Sept 18, 2026 - The Life Sciences Innovation Forum (LSIF), the investment platform of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026), brought 23 biotechnology companies from eight countries to Riyadh to pitch to investors, judges, and leaders of the Kingdom's life sciences ecosystem. Companies from eight countries pitched to investors across five scientific heats, with Saudi Arabia the second-largest market represented. Dr Abdulaziz Alrifi, Director Of Partnerships, KAIMRC, stated, "We were proud to welcome leading investment firms that expressed their willingness to invest more than $USD 120 milliond in promising biotech opportunities emerging from LSIF 2026. The journey culminated with the announcement of the LSIF 2026 Grand Winner: Bilix from South Korea." On winning, a representative of Bilix enthused, "Winning LSIF 2026 is a great honor, however the real win is scaling our startup with the Kingdom's research ecosystem" Where RGMBS 2026 set out the scale of Saudi Arabia's biotechnology ambition, LSIF put that ambition in front of the founders and investors who will shape the sector's next decade. The United States led the cohort with eight companies, with Saudi Arabia second at four, followed by South Korea, the United Kingdom, Australia, France, Germany, and Switzerland. Several international companies presented pathways to localization, research, or clinical development in the Kingdom. FIVE HEATS, ONE FRONTIER Companies competed across five heats, each at the leading edge of life sciences innovation. AI and Bio Data. Amprologix of the United Kingdom presented AI-assisted discovery of narrow-spectrum peptide antibiotics targeting drug-resistant pathogens. Pneumatica Bio of Australia combines mechanistic modelling, machine learning, and automated cell experiments to better predict human therapeutic response, while Saudi company LinusBio MENA presented precision exposomics built on hair-based biomarker profiling. Vaccine Development and Biomanufacturing. Biotech Innovations Company of Saudi Arabia presented a recombinant-protein MERS-CoV vaccine program focused on regional biosecurity and local manufacturing. OctoCells of France presented an animal-free 3D bioscaffold platform designed to reduce the water, infrastructure, and manufacturing burden of producing biologics and cell therapies, and Cevza Therapeutics of Australia an RNA therapy platform with planned research and development localization in the Kingdom. Cellular Therapy and Gene Editing. CellKure of the United States highlighted Phase 1 results for its multi-antigen T-cell therapy in acute myeloid leukemia. MVRIX of South Korea presented an in vivo CAR-T approach using targeted mRNA delivery, and Saudi company Medixcel a platform to bring cell and gene therapy capabilities, partnerships, and manufacturing into the Kingdom. Bioengineering and Synthetic Biology. NanoZymeX of Switzerland presented a lipid nanoparticle platform to improve enzyme replacement therapy for lysosomal storage diseases, beginning with Pompe disease. AUREXO Therapeutics of the United States presented engineered bacterial vesicles for precision oncology, and Ingenskin Therapeutics of France an autologous skin substitute for chronic wounds, burns, and trauma. Diagnostics and Drug Discovery. SiNON Nano Sciences of the United States presented a carbon nanoparticle platform designed to cross the blood-brain barrier. Spirea of the United Kingdom presented a dual-payload antibody-drug conjugate platform to address cancer drug resistance, and Accanito Therapeutics of the United States a clinical-stage oncology platform with a proposal for technology transfer and local manufacturing in Saudi Arabia. Questions from judges and the audience concentrated on turning science into treatments: regulatory routes, clinical evidence, manufacturing scale-up, localization economics, and intellectual property. LSIF 2026 was sponsored by Chiyoda Corporation. Alongside Grand Winner Bilix, four category awards were presented: the Most Scalable Biotech Startup Award to CellKure, the Outstanding Founding Team Award to Quantabia, the Breakthrough Science Award to Swaza, and the Innovation Excellence Award to Agemica. LSIF 2026 took place as part of RGMBS 2026, held from 14 to 16 September in Riyadh. The Summit was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment, Invest Saudi, and the Saudi Data & AI Authority (SDAIA) serving as key strategic partners. About The Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org FOR FURTHER INFORMATION Email: [email protected] Telephone: +966 559 810 777
- Riyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia's Commitment to Lead the Future of BiotechnologyRIYADH, KSA, Sept 18, 2026 - The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia's ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom's leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place. More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh. The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony. Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit's work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love. FOUR PILLARS, ONE NATIONAL MISSION RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom's entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom's essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities' Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master's programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon. THREE DAYS ON THE MAIN STAGE Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony. "RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope. "Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families." H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS . RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom's place at the forefront of global biotechnology in the years ahead. About The Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org FOR FURTHER INFORMATION Email: [email protected] Telephone: +966 559 810 777